First AD

Second AD

Dr Voss Application of Updated KEYNOTE-564 Data

Now that many patients are getting adjuvant pembrolizumab based on KEYNOTE-564 and recent OS data presented(KEYNOTE-564 update (

Choueiri et al., ASCO GU 2024 Abstract LBA359

How does that change your management for patients that progress?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Video Series

ASCO 2024: Updates in the Treatment of Advanced Renal Cell Carcinoma

Peer Exchange

Martin Voss, MD, elaborates on the impact of the KEYNOTE-564 trial and its recently presented data on the management of renal cell carcinoma, highlighting how these findings have influenced treatment decisions and patient care strategies. 